+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The new EU regulation on in vitro diagnostics: potential issues at the interface of medicines and companion diagnostics



The new EU regulation on in vitro diagnostics: potential issues at the interface of medicines and companion diagnostics



Biomarkers in Medicine 10(12): 1261-1268



The new European regulation for in vitro diagnostics (IVD) divides the certification of IVD including companion diagnostics (CDx) by notified bodies (NB) from the market authorization of medicines. With the new regulation, CDx will require conformity assessment which is expected to include clinical evidence by NB. This is a significant change from the current situation: until now most IVD have been certified based on their manufacturers' assessment. For one medicine assessed by the EMA, certification of several different CDx by different NB is possible. As the benefit-risk balance of the medicine may depend on the performance (e.g., sensitivity and specificity) of its CDx, a close cooperation of EMA and NB will be necessary. The availability of detailed information on CDx used in the pivotal clinical trials for the medicine's authorization will become crucial for the assessment of alternative or competing CDx.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 059089001

Download citation: RISBibTeXText

PMID: 27661101

DOI: 10.2217/bmm-2016-0233


Related references

Progress and potential of RAS mutation detection for diagnostics and companion diagnostics. Expert Review of Molecular Diagnostics 16(10): 1067-1072, 2016

Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer. Journal of Personalized Medicine 6(1):, 2016

The economic value of companion diagnostics and stratified medicines. Expert Review of Molecular Diagnostics 12(8): 791-794, 2012

Aligning the economic value of companion diagnostics and stratified medicines. Journal of Personalized Medicine 2(4): 257-266, 2012

Using companion and coupled diagnostics within strategy to personalize targeted medicines. Personalized Medicine 9(7): 751-761, 2012

The impact of new trends in POCTs for companion diagnostics, non-invasive testing and molecular diagnostics. Expert Review of Molecular Diagnostics 15(6): 815-827, 2015

Models of partnership between the pharmaceutical and diagnostics industries around companion diagnostics for cancer and beyond. Expert Opinion on Medical Diagnostics 5(2): 91-94, 2011

Diagnostics and personalized medicine: observations from the World Companion Diagnostics Summit. Pharmacogenomics 12(4): 465-470, 2011

Personalized medicine, pharmacogenomics, and companion diagnostics. Current and future applications of molecular diagnostics will influence these emerging fields. Mlo: Medical Laboratory Observer 47(2): 22-23, 2015

Current issues regarding companion diagnostics and future prospects. Rinsho Byori. Japanese Journal of Clinical Pathology 62(4): 381-389, 2014

Companion diagnostics: significances and issues in its clinical application. Rinsho Byori. Japanese Journal of Clinical Pathology 59(6): 602-609, 2011

Companion diagnostics: emerging strategies and issues in pharmaceutical development. Expert Review of Molecular Diagnostics 12(6): 561-563, 2012

Current Trends in Personalized Medicine and Companion Diagnostics: A Summary From the DIA Meeting on Personalized Medicine and Companion Diagnostics. Therapeutic Innovation and Regulatory Science 49(4): 530-543, 2015

The evolving potential of companion diagnostics. Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum 245: S22-S25, 2016

The Regulation of Companion Diagnostics: A Global Perspective. Therapeutic Innovation and Regulatory Science 47(4): 405-415, 2013